Trial of Oxford-AstraZeneca Corona vaccine to be launched in India soon, Serum Institute expects

The corona virus epidemic continues to wreak havoc around the world. Meanwhile, scientists in many countries of the world are busy preparing the Corona virus vaccine. In this episode, the Oxford-AstraZeneca Corona virus vaccine trial in the UK was interrupted this week for safety reasons. The trial of this vaccine is being done jointly by Oxford University of Britain and pharma company AstraZeneca. Trial of this vaccine is going on in India also. Testing of this vaccine has been stopped in India for safety reasons. Meanwhile, a relief news came from Britain.

Trial of Oxford-AstraZeneca Corona vaccine to be launched in India soon, Serum Institute expects

The Oxford-AstraZeneca Corona virus vaccine trial has been resumed once again in the UK on Saturday. Hours after clinical trials for the Oxford University Corona virus Vaccine, there is news of a reprieve from India. India's pharma major Serum Institute of India (SII) has said that as soon as the Drug Controller General of India (DCGI) approves it, testing of the Oxford-AstraAnica corona virus vaccine will resume in India.

Oxford-AstraZeneca's trial of the corona virus vaccine was halted on 6 September because a person involved in the vaccine trial developed unexplained disease. Human trials of the Corona waxen of Oxford-AstraZeneca were conducted in other countries, including the US, Britain, Brazil and South Africa.

Following the developments, India's top drugs regulator Drugs Controller General of India (DCGI) asked the Serum Institute of India (SII) to postpone any new recruitment in phase two and phase three trials of the COVID-9 vaccine until further orders. said. When asked for DCGI, the pharma company has been instructed to increase the safety monitoring of already vaccinated subjects and vaccinate the candidate and submit their plans and reports.

Officials said that SII will now have to seek approval from the Data and Safety Monitoring Board (DSMB), UK and DSMB India to get clearance from DCGI's office. Serum Institute of India said in its statement that once DCGI will allow us to resume testing in India, we will resume testing.

Explain that the vaccine will be produced by the Serum Institute in India in technical collaboration with Oxford University and AstraZeneca, who have developed the vaccine.

The test will be reinstated in India upon approval -

The Pune-based vaccine manufacturer Serum Institute of India (SII) said it would resume clinical trials of the Oxford-Astragena Covid-19 vaccine after receiving approval from the Drug Controller General (DCGI) in the country.

At the same time, SII CEO Adar Poonawala tweeted, as I mentioned earlier, that we should not jump to the results until the trial is over. The recent chain of events is a clear example that we should not prejudice the process and respect it. End-to-end process.

Despite being vaccinated, there is no hope of a normal life by the end of 2021

Infectious disease consultant Anthony Fossey of the US says that normal life is not expected to return until the end of 2021, despite receiving the Corona virus vaccine.

"If you're talking about life before Covid-19, it's difficult at the moment," Fossey said. Assume that normal life cannot return until the end of next year.

Trial of Oxford-AstraZeneca Corona vaccine to be launched in India soon, Serum Institute expects

Hopefully, the vaccine will form and help normalize life, but not as much as we expected.

Addressing a program called the Global Fight Webinar, he said, the US Department of Food and Drug could get the right to use the vaccine emergency later this year or early next year. But the vaccine will not be immediately available to everyone. Vaccination of large populations will take time and 2021 may also pass.

The challenge of keeping vaccines cool 

"Keeping the Corona virus vaccines cold will be a major challenge for many countries," Fossey said. Corona vaccines should be kept if they are frozen. Cold storage is still a major issue in many countries.

Corona vaccine to receive 100 million people in 2020-21, Russia claims

Almost the whole world is waiting for the corona virus vaccine, while Russia is also giving vaccine supplements to its citizens. Recently, Russia has released the first batch of 'Sputnik-V', considered the world's first corona vaccine for ordinary citizens. According to a report, now Russia has announced that it will vaccinate over one billion i.e. 100 crore people within 2020-2021. The news agency Reuters has given this information citing Interfax news agency.

The Russian Direct Investment Fund (RDIF) has already signed an agreement to export the Corona vaccine to Brazil and the Bahia state abroad. In addition, there is an agreement with Kazakhstan, which is initially ready to purchase more than 2 million vaccine supplements and can later expand it to 50 million.

According to reports, 300 million doses of the Russian vaccine will be produced in India. However, the biggest thing is that Phase III testing of this vaccine has not been done yet. From this month, its trial will start in India. According to Kirill Dmitriev, CEO of the Russian Direct Investment Fund, trials will begin in India, including India, in the United Arab Emirates, Saudi Arabia, the Philippines and Brazil.

Russian President Vladimir Putin launched the ut Sputnik-V vaccine on 11 August and explained its effectiveness. He told that the vaccine is completely safe and effective and because of this his daughter has also taken vaccine supplements. Later, during an interview, he also stated that his daughter is completely safe and healthy after taking the vaccine.

Let us tell you that this vaccine from Russia has been developed by Gamalaya Research Institute of Moscow. Recently, a report on the initial testing of this vaccine was published in a magazine called Lancet, stating that the vaccine was found to be safe during testing. People have not seen its side effects and after taking the vaccine, antibodies have also been prepared in them.